<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Treatment Algorithm and Medication for Benign Prostatic Hyperplasia (BPH)</title>
  <meta charset="utf-8">
  
  <link href="urology.css" rel="stylesheet">

<meta name="keywords" content="benign prostatic hyperplasia treatment, bph treatment, prostate enlargement treatment" >
<meta name="description" content="Algorithm for diagnosis and treatment of benign prostate hyperplasia (BPH), from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <h5 id="logo">urology-textbook.com</h5>
       <p>Dr. med. Dirk Manski</p>
    </a>  
</header>
<main>
<nav id="navigation">
<ul>
<li><a href="https://www.urology-textbook.com/index.html">Start</a></li>
<li><a href="https://www.urology-textbook.com/anatomy.html">Anatomy</a></li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>



 
</nav>
<article>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/prostate.html">Prostate</a> &gt; <a href="https://www.urology-textbook.com/benign-prostatic-hyperplasia.html">BPH</a> &gt; Treatment algorithm</p><!-- Main content -->
<h1>Treatment Algorithm and Medication for Benign Prostatic Hyperplasia (BPH)</h1>

<ul title="benign prostatic hyperplasia">
<li><a href="https://www.urology-textbook.com/benign-prostatic-hyperplasia.html">Benign prostatic hyperplasia: definitions, epidemiology and etiology</a></li>
<li><a href="https://www.urology-textbook.com/bph-symptoms.html">Benign prostatic hyperplasia: signs and symptoms</a></li>
<li><a href="https://www.urology-textbook.com/bph-diagnosis.html">Benign prostatic hyperplasia: diagnosis</a></li>
<li><strong>Benign prostatic hyperplasia: treatment algorithm</strong></li>

<li><a href="https://www.urology-textbook.com/bph-surgery.html">Benign prostatic hyperplasia: surgical treatment</a></li>
</ul>

<br>
<p>Review literature: (Burnett und Wein, 2006) (DGU guideline) (EAU guideline: <a href="https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/">Non-neurogenic male LUTS</a>)</p>


<h2>Basic Principles of BPH Therapy</h2>

    <ul>
        <li>Watchful Waiting: Watchful Waiting is possible if surgery is not needed and the patient accepts his (moderate) symptoms.</li>
        <li>Medical treatment: is indicated for significant and disturbing symptoms and if surgical therapy is not needed (see below). The following drug classes for treating BPH are available, some drugs may be combined: herbal extracts, alpha blocker, 5&alpha;-reductase inhibitors, anticholinergics, &beta;3 adrenergic receptor agonists, and phosphodiesterase inhibitors.</li>
        <li>
        Surgical treatment of BPH: insufficient medical therapy, postrenal kidney failure, recurrent urinary retention, recurrent urinary tract infections, recurrent hematuria, and significant bladder diverticula are indications for surgery. Standard surgical techniques are:
        <ul>
            <li>Small prostate volume (below 40 ml): transurethral incision of the prostate (TUIP), transurethral resection of the prostate (TURP), or laser vaporization of the prostate.</li>
            <li>Medium prostate volume (40&ndash;100 ml): TURP, endoscopic enucleation of the prostate (EEP), or laser vaporization of the prostate.</li>
            <li>Large prostate volume (&gt;75 ml): open or endoscopic enucleation of the prostate. If the treatment of a bladder diverticulum or large bladder stones is necessary, an open prostatectomy may be useful even with a smaller prostate volume.</li>
        </ul>
        </li>
    </ul>
    
    <h2>Algorithm for Initial Diagnosis and Treatment of Men with LUTS due to BPH</h2>

<br>
 <a NAME="luts_flowchart"> </a>
<table width=100%>
<caption><strong>Fig. algorithm of BPH:</strong> flowchart for diagnosis and treatment of BPH at initial presentation, in accordance to the guidelines of the AUA, DGU and EAU:<br>
(*) Despite adequate medical therapy. <br>
(**) Urodynamics should be considered in men under 50 years, in patients over 80 years, with more than 300 ml residual urine, maximum urinary flow &gt;15 ml/s, suspected <a href="https://www.urology-textbook.com/neurogenic-lower-urinary-tract-dysfunction.html">neurogenic bladder dysfunction</a>, after radical pelvic surgery, and unsuccessful non-invasive therapy. <br>
(***) It is not an option after <a href="https://www.urology-textbook.com/urinary-retention.html">urinary retention</a> or <a href="https://www.urology-textbook.com/hematuria.html">hematuria</a>.
</caption>
<tr><td><img src="https://images1.urology-textbook.com/luts_flowchart.jpg" alt="Fig. diagnostic workup of LUTS: algorithm for diagnosis and treatment of BPH at initial presentation, in accordance to the guidelines of AUA, DGU and EAU"></td> </tr>
</table>


<h2>Watchful waiting in BPH</h2> 
<p>Watchful waiting in BPH is possible if there is no need for surgery and the patient accepts his (moderate) symptoms. 40% of the patients initially assigned to watchful waiting experience improvement of symptoms. 10&ndash;27% of the patients are going to have surgery for disease progression; risk factors are prostate volume (&gt;40 ml), <a href="https://www.urology-textbook.com/psa-test.html">PSA concentration</a> (&gt;3.2 mg/ml), and a <a href="https://www.urology-textbook.com/bph-symptoms.html#ipss">high IPSS</a>. </p>

<h2>Alpha Blockers for Benign Prostatic Hyperplasia (BPH)</h2>

<p>Alpha blockers are the drugs of first choice to treat LUTS due to BPH. Numerous randomized trials have demonstrated the efficacy and safety of the alpha blocker listed below. Furthermore, an alpha blocker should be given to support a trial without a catheter after urinary retention. See also the section <a href="https://www.urology-textbook.com/alpha-blocker.html">pharmacology and side effects of alpha blocker</a>. </p>

<h3>Tamsulosin:</h3> 
<p>The dosage of <a href="https://www.urology-textbook.com/tamsulosin.html">tamsulosin</a> is 0.4 mg 1-0-0 p.o. A low starting dosage is not necessary. The OCAS galenic (Oral Controlled Absorption System) enables dosing independent from meals. </p>

<h3>Alfuzosin:</h3>

<p>The dosage of <a href="https://www.urology-textbook.com/alfuzosin.html">alfuzosin</a> is 2.5 mg 1-1-1 or 5 mg 1-0-1 p.o. A low starting dosage is not necessary. The sustained-release galenic enables a single dose of 5&ndash;10 mg 1-0-0 p.o. </p>

<h3>Silodosin:</h3>
<p><a href="https://www.urology-textbook.com/silodosin.html">Silodosin</a> is a new selective alpha blocker with few side effects on the cardiovascular system. Dosage 8 mg 1-0-0 p.o. A dose reduction to 4 mg is necessary in <a href="https://www.urology-textbook.com/chronic-kidney-disease.html">chronic kidney disease</a>. A low starting dosage is not necessary. </p>

<h3>Terazosin:</h3> 
<p>Terazosin is a drug of second choice because of the side effects, but it may be beneficial in patients with arterial hypertension. The dosage of <a href="https://www.urology-textbook.com/terazosin.html">terazosin</a> must start with a low dose in the evening before bedtime (1 mg 0-0-1 p.o.) to avoid side effects on the arterial blood pressure. The dose may be increased weekly to 2 mg, 5 mg, or 10 mg once daily to achieve the desired improvement of symptoms.  </p>

<h3>Doxazosin:</h3> <p>Doxazosin is a drug of second choice because of its side effects, but it may benefit patients with arterial hypertension. The dosage of <a href="https://www.urology-textbook.com/doxazosin.html">doxazosin</a> must start with a low dose in the evening before bedtime (1 mg 0-0-1 p.o.) to avoid side effects on arterial blood pressure. The dose may be increased weekly to 2 mg, 5 mg, or 10 mg once daily to achieve the desired improvement of symptoms.  </p>

<h3>Comparison of Alpha Blocker:</h3> 
<p>The analysis of placebo-controlled trials shows that terazosin and doxazosin are more effective, but this leads to a higher rate of side effects (e.g., dizziness, weakness, postural hypotension). The advantages of alfuzosin and tamsulosin are reduced side effects and the lack of necessity for dose titration.</p>

<h3>BPH and Accompanying Arterial Hypertension:</h3> 
<p>Alpha blockers for arterial hypertension proved inferior to beta-blocker and ACE inhibitors (ALLHAT, 2000). Therefore, alpha blockers are not recommended as first-line treatment for arterial hypertension. This also applies to patients with arterial hypertension and BPH: it is more beneficial to treat arterial hypertension with a drug of first choice and to treat BPH with a selective alpha <sub>1A</sub>-blocker.</p>

<h2>5&alpha;-Reductase Inhibitors for Benign Prostatic Hyperplasia (BPH)</h2>

<p><a href="https://www.urology-textbook.com/male-hormones-testosterone.html#androgens">Dihydrotestosterone (DHT) is the main androgen</a> for the prostate; it is converted from <a href="https://www.urology-textbook.com/testosterone-serum-test.html">testosterone</a> by the 5&alpha;-reductase. <a href="https://www.urology-textbook.com/finasteride.html">Finasteride</a> is a competitive inhibitor of the 5&alpha;-reductase type 2, leading to lower concentrations of dihydrotestosterone (DHT) in the prostate. DHT is the only effective androgen on the prostate; thus, a selective androgen deprivation of the prostate is possible. <a href="https://www.urology-textbook.com/dutasteride.html">Dutasteride</a> is a 5&alpha;-reductase inhibitor that acts on type 1 and 2 isoenzymes of the 5&alpha;-reductase.</p>

<p>The consequence of 5&alpha;-reductase inhibition is the shrinkage of the prostate (7&ndash;13 ml in 12 months), improvement of LUTS (decreasing IPSS), and improved urinary flow (maximum flow 0.6&ndash;1.6 ml/s better than placebo). The mechanism of action is slow; a significant clinical effect can be expected after a treatment period of 1 year. The larger the prostate, the greater the therapeutic effect. After five years of treatment, there is a significant risk reduction for urinary retention (3% vs. 7%), gross hematuria or the need for TURP (5% vs. 10%) (McConnell et al., 1998). The shrinking of the prostate also decreases the PSA concentration (up to 50%).</p>

<h3>Pharmacokinetics and Side Effects of 5&alpha;-Reductase Inhibitors</h3> 
<p>5&alpha;-reductase inhibitors are well tolerated, and the safety of the drugs was documented in several long trials, for details see sections finasteride and dutasteride. Both substances reduce the <a href="https://www.urology-textbook.com/prostate-cancer.html">incidence of prostate cancer</a> if given over several years (Andriole et al., 2004). This led to the initiation of prostate cancer prevention trials, such as the REDUCE trial [see section prevention of prostate cancer].</p>

<h3>Dosage of 5&alpha;-Reductase Inhibitors:</h3>
<p>Finasteride 5 mg p.o. once daily, dutasteride 0,5 mg p.o. once daily.</p>


<h2>Phosphodiesterase Inhibitors for BPH</h2>
<p>Smooth muscle cells of the prostate and urinary bladder also express type 4 and type 5 phosphodiesterase. Randomized trials show that treatment with tadalafil relieves BPH symptoms (Laydner et al., 2011). The therapeutic effect of tadalafil is comparable to tamsulosin, and erectile function improves (Oelke et al., 2012). Tadalafil has been approved for the therapy of BPH since 2012, and the dosage is 5 mg once daily. </p>

<h2>Anticholinergics for Benign Prostatic Hyperplasia (BPH)</h2>
<p>Storage symptoms without significant residual urine may be treated with anticholinergic drugs. Trials have shown that there is only a low risk for urinary retention. Alternatively, newly approved &beta;3 adrenergic receptor agonists such as mirabegron can be used in cases of intolerance or lack of efficacy. Anticholinergic drugs may be combined with an alpha blocker if there is significant obstruction. The combination therapy increases the side effects.</p>

<h2>Treatment of Nocturia</h2>
<p>Nocturia is a distressing symptom that BPH can cause, but also numerous other conditions, see section <a href="https://www.urology-textbook.com/nocturia.html">nocturia</a>. It is essential to rule out internal medicine diseases causing nocturia before starting treatment: control diuretic medication and exclude cardiac, pulmonary, neurological, or metabolic causes of nocturia.</p>

<ul>
   <li>Micturition diary: to diagnose nocturnal polyuria and bladder storage disorders. </li>
    <li>Behavioral therapy: optimizing sleep hygiene and refraining from evening fluids and alcohol is important.</li>
    <li>Urological treatment: conservative or, if necessary, surgical therapy of BPH for voiding symptoms or residual urine. <a href="https://www.urology-textbook.com/overactive-bladder.html">Therapy of overactive bladder</a> in case of storage symptoms. </li>
    <li>Desmopressin: is an option if nocturia persists despite the above-mentioned measures. Dosage of desmopressin: 50 &mu;g before bedtime for men and 25 &mu;g for women (Han et al., 2017). For pharmacology, contraindications, and side effects, see <a href="desmopressin.html">desmopressin</a>.</li>
    </ul>

<h2>Drug Combinations for the Treatment of Benign Prostatic Hyperplasia (BPH)</h2>

<p>Sound drug combinations are the administration of an alpha blocker for rapid symptom improvement and a 5&alpha;-reductase inhibitor for long-term prostate volume reduction. The efficiency and safety of the combination was demonstrated in randomized trials. The alpha blocker may be stopped in the further course of the treatment.</p>

<p>Another useful combination is the administration of anticholinergics for storage symptoms and an alpha blocker for voiding symptoms.</p>



<h2>Phytotherapeutic Drugs for Benign Prostatic Hyperplasia (BPH)</h2>

<p>Mono extracts or combinations of plant extracts from Sabal serrulata (dwarf palm), Serenoa repens (saw palmetto), Pygeum africanum (African plum), beta-Sitosterone from Hypoxis rooperi (African grass), Secale cereale (rye) and many more are available over the counter. Suspected mechanisms of action include the inhibition of 5&alpha;-reductase (Serenoa repens), the inhibition of growth factors (Pygeum africanum), promotion of apoptosis (Serenoa repens), anti-inflammatory effects, placebo effects and many more. Only a few well-structured randomized trials indicate a moderate effect of plant extracts, the effect of Serenoa repens (Saw Palmetto) is documented best. Trials documenting the long-term efficiency and safety of plant extract are not available. </p>

<br>
<br>

<table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/bph-diagnosis.html">BPH diagnosis</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/bph-surgery.html">BPH Surgery</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<p><a NAME="Andriole2004">
    Andriole u.a. 2004 A<SMALL>NDRIOLE</SMALL>, G.&nbsp;L.&nbsp;;
      R<SMALL>OEHRBORN</SMALL>, C.&nbsp;; S<SMALL>CHULMAN</SMALL>, C.&nbsp;; S<SMALL>LAWIN</SMALL>, K.&nbsp;M.&nbsp;;
      S<SMALL>OMERVILLE</SMALL>, M.&nbsp;; R<SMALL>ITTMASTER</SMALL>, R.&nbsp;S.:
    </a>
     Effect of <a href="https://www.urologielehrbuch.de/dutasterid.html">dutasteride</a> on the detection of prostate cancer in men with
      benign prostatic hyperplasia.
    <br> In: <I>Urology</I>
    <br> 64 (2004), Nr.&nbsp;3, S.&nbsp;537&ndash;41; discussion 542&ndash;3</p>


<p><a NAME="Burnett2006">
    Burnett und Wein 2006 B<SMALL>URNETT</SMALL>, A.&nbsp;L.&nbsp;; W<SMALL>EIN</SMALL>,
      A.&nbsp;J.:
    </a>
     Benign prostatic hyperplasia in primary care: what you need to know.
    <br> In: <I>J Urol</I>
    <br> 175 (2006), Nr.&nbsp;3 Pt 2, S.&nbsp;S19&ndash;24</p>


<p><a NAME="Chapple2004a">
    Chapple 2004 C<SMALL>HAPPLE</SMALL>, C.&nbsp;R.:
    </a>
     Pharmacological therapy of benign prostatic hyperplasia/lower urinary
      tract symptoms: an overview for the practising clinician.
    <br> In: <I>BJU Int</I>
    <br> 94 (2004), Nr.&nbsp;5, S.&nbsp;738&ndash;44</p>


<p>DGU Guideline, “S2e Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS).,” 2023. [Online]. Available: <a href="https://register.awmf.org/assets/guidelines/043-034l_S2e_Diagnostik_Therapie_benignes_Prostatasyndrom_2023-04.pdf">https://register.awmf.org/assets/guidelines/043-034l_S2e_Diagnostik_Therapie_benignes_Prostatasyndrom_2023-04.pdf</a></p>  
    
 
<p><a NAME="Donovan2000">
    Donovan u.a. 2000 D<SMALL>ONOVAN</SMALL>, J.&nbsp;L.&nbsp;; P<SMALL>ETERS</SMALL>,
      T.&nbsp;J.&nbsp;; N<SMALL>EAL</SMALL>, D.&nbsp;E.&nbsp;; B<SMALL>ROOKES</SMALL>, S.&nbsp;T.&nbsp;; G<SMALL>UJRAL</SMALL>,
      S.&nbsp;; C<SMALL>HACKO</SMALL>, K.&nbsp;N.&nbsp;; W<SMALL>RIGHT</SMALL>, M.&nbsp;; K<SMALL>ENNEDY</SMALL>, L.&nbsp;G.&nbsp;;
      A<SMALL>BRAMS</SMALL>, P.:
    </a>
     A randomized trial comparing transurethral resection of the prostate,
      laser therapy and conservative treatment of men with symptoms associated with
      benign prostatic enlargement: The CLasP study.
    <br> In: <I>J Urol</I>
    <br> 164 (2000), Nr.&nbsp;1, S.&nbsp;65&ndash;70</p>
    
<p>“EAU Guideline: Non-neurogenic Male LUTS,” Available: <a href="https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/">https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/</a>.</p>


<p>Kopp, R. P.; Freedland, S. J. &amp; Parsons, J. K.
    Associations 
        of benign prostatic hyperplasia with prostate cancer: the debate continues.<br><em>Eur 
        Urol, </em><b>2011</b><i>, 60</i>, 699-700; discussion 701-2.</p>


<p>&#216;rsted, D. D.; Bojesen, S. E.; Nielsen, S. F. &amp; 
        Nordestgaard, B. G.
        Association of clinical benign prostate hyperplasia 
        with prostate cancer incidence and mortality revisited: a nationwide 
        cohort study of 3,009,258 men.<br><em>Eur Urol, </em><b>2011</b><i>, 60</i>, 
        691-698.</p>
    
    
<p>Parsons, J. Kellogg; Messer, Karen; White, Martha; 
        Barrett-Connor, Elizabeth; Bauer, Douglas C; Marshall, Lynn M; in Men 
        (MrOS) Research Group, Osteoporotic Fractures &amp; the Urologic Diseases in 
        America Project
        Obesity increases and physical activity decreases lower 
        urinary tract symptom risk in older men: the Osteoporotic Fractures in Men 
        study.<br><em>Eur Urol, </em><b>2011</b><i>, 60</i>, 1173-1180.</p>


<p><a NAME="Reich2006">
    Reich u.a. 2006 R<SMALL>EICH</SMALL>, O.&nbsp;; G<SMALL>RATZKE</SMALL>, C.&nbsp;;
      S<SMALL>TIEF</SMALL>, C.&nbsp;G.:
    </a>
     Techniques and long-term results of surgical procedures for BPH.
    <br> In: <I>Eur Urol</I>
    <br> 49 (2006), Nr.&nbsp;6, S.&nbsp;970&ndash;8; discussion 978</p>

<p><a NAME="Uygur1998b">
    Uygur u.a. 1998 U<SMALL>YGUR</SMALL>, M.&nbsp;C.&nbsp;; G<SMALL>UR</SMALL>, E.&nbsp;;
      A<SMALL>RIK</SMALL>, A.&nbsp;I.&nbsp;; A<SMALL>LTUG</SMALL>, U.&nbsp;; E<SMALL>ROL</SMALL>, D.:
    </a>
     Erectile dysfunction following treatments of benign prostatic
      hyperplasia: a prospective study.
    <br> In: <I>Andrologia</I>
    <br> 30 (1998), Nr.&nbsp;1, S.&nbsp;5&ndash;10</p>
 
<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/bph_benigne_prostatahyperplasie_06.html">Therapie der benignen Prostatahyperplasie</a></p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
